Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will participate at the Cowen 44th Annual Health Care Conference with the management team holding one-on-one investor meetings on March 4, 2024.
Cowen’s 44th Annual Health Care Conference is taking place March 4 - 6, 2024, at the Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats, and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.
About Tvardi Therapeutics
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company is conducting Phase 2 clinical trials in STAT3-driven diseases: hepatocellular carcinoma (NCT05440708) and idiopathic pulmonary fibrosis (NCT05671835). To learn more, please visit tvardi.com or follow us on LinkedIn and X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301145891/en/
Source: Tvardi Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240301145891/en
